Price (delayed)
$5.045
Market cap
$272.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.59
Enterprise value
$209.91M
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is
There are no recent dividends present for CARA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.